
NCPW 2025: Fighting against Deceptive Marketing
If you’ve been misled by an ad, regulators want to hear from you. We do too.
Heermann et al. v. Alchemee, LLC et al.
24-cv-7550, W.D. Mo.
(March 2024)
Howard et al. v. Alchemee, LLC and Taro Pharmaceutical USA, Inc.
24-cv-1834, C.D. Cal.
(March 2024)
Judt et al. v. Alchemee, LLC and Taro Pharmaceuticals U.S.A., Inc.
24-cv-2718, S.D.N.Y.
(April 2024)
O’Dea et al. v. Alchemee, LLC and Taro Pharmaceuticals U.S.A., Inc.
24-cv-2755, N.D. Ill.
(April 2024)
Ramos et al. v. Alchemee, LLC
24-cv-2230, N.D. Cal.
(March 2024)
Teron et al. v. Alchemee, LLC and Taro Pharmaceuticals U.S.A., Inc.
24-cv-7538, N.D. Cal.
(March 2024)
Proactiv
Misleadingly representing that products were safe when they contained, or were at risk of containing, the carcinogen benzene
Heermann case: Pending
Howard cases: Dismissed
Judt case: Voluntarily dismissed When a complaint is dismissed without prejudice, an amended version of the complaint can be refiled.
O’Dea case: Pending
Ramos case: Pending
Teron case: Pending
If you’ve been misled by an ad, regulators want to hear from you. We do too.
It’s easier to rack up hidden fees than it is to cancel.
The only thing more “ridiculous” than the touted benefits is the cancellation process.
Under a proposed bill, theaters could be fined for making moviegoers guess.
Money-back guarantee comes up woefully short of advertised percentage.